Evercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck

9/14/22 8:09:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Durable Goods

Consumer Discretionary

Get the next $AKRO alert in real time by email

Berenberg raised the price target for Merck & Co., Inc. (NYSE:MRK) from $95 to $100. Merck shares rose 0.7% to $86.22 in pre-market trading.
Wells Fargo cut the price target on Eastman Chemical Company (NYSE:EMN) from $110 to $95. Eastman Chemical shares fell 0.4% to $83.00 in pre-market trading.
Evercore ISI Group increased Akero Therapeutics, Inc. (NASDAQ:AKRO) price target from $10 to $50. Akero Therapeutics shares fell 1.2% to $28.70 in pre-market trading.
Telsey Advisory Group lowered the price target on Stitch Fix, Inc. (NASDAQ:SFIX) from $10 to $8. Stitch Fix shares fell 13.3% to close at $4.90 on Tuesday.
Morgan Stanley boosted price target for Motorola Solutions, Inc. (NYSE:MSI) from $240 to $260. Motorola Solutions shares rose 0.1% to $245.33 in pre-market trading.
Wedbush increased the price target on Starbucks Corporation (NASDAQ:SBUX) from $86 to $92. Starbucks shares rose 1.6% to $89.25 in pre-market trading.
B of A Securities boosted the price target for RBC Bearings Incorporated (NASDAQ:ROLL) from $193 to $235. RBC Bearings fell 1.2% to $239.80 in pre-market trading.
Goldman Sachs raised the price target on Regal Rexnord Corporation (NYSE:RRX) from $165 to $187. Regal Rexnord fell 2.5% to close at $143.39 on Tuesday.
Credit Suisse raised the price target on Core & Main, Inc. (NYSE:CNM) from $29 to $32. Core & Main shares fell 0.5% to $24.99 in pre-market trading.
Raymond James increased the price target on Farmland Partners Inc. (NYSE:FPI) from $15 to $17. Farmland Partners shares fell 2.3% to close at $14.33 on Tuesday.

Don’t forget to check out our premarket coverage here .

Check out this: US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus

Get the next $AKRO alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$AKRO
$CNM
$EMN
$FPI

Company	Date	Price Target	Rating	Analyst
Starbucks Corporation $SBUX	1/30/2026	$110.00 → $116.00	Overweight	Barclays
Starbucks Corporation $SBUX	1/30/2026	$100.00 → $103.00	Overweight	Piper Sandler
Starbucks Corporation $SBUX	1/23/2026		Mkt Perform → Outperform	William Blair
Eastman Chemical Company $EMN	1/16/2026	$70.00	Outperform → Sector Perform	RBC Capital Mkts
Merck & Company Inc. $MRK	1/8/2026	$135.00	Peer Perform → Outperform	Wolfe Research
Motorola Solutions Inc. $MSI	1/5/2026	$443.00	Neutral → Overweight	Piper Sandler
Eastman Chemical Company $EMN	12/19/2025	$70.00	Overweight → Equal Weight	Wells Fargo
Merck & Company Inc. $MRK	12/18/2025	$130.00	Market Perform → Outperform	BMO Capital Markets

More analyst ratings

$AKRO
$CNM
$EMN
$FPI
Press Releases

Fastest customizable press release news feed in the world

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

2/11/26 5:31:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Motorola Solutions Reports Fourth-Quarter and Full-Year Financial Results

Company achieves record full-year revenue, earnings, cash flow and ending backlog Sales of $3.4 billion, up 12% from Q4 in the prior year; up 8% for full year Products and Systems Integration sales grew 11% in Q4; up 5% for full year Software and Services sales grew 15% in Q4; up 13% for full year GAAP Q4 earnings per share (EPS) of $3.86, up 8%; $12.75 for full year, up 38% Non-GAAP Q4 EPS* of $4.59, up 14%; $15.38 for full year, up 11% Generated $1.3 billion of operating cash flow in Q4; $2.8 billion for full year, up 19% Repurchased $490 million of shares and paid $182 million in dividends in Q4 Record ending backlog of $15.7 billion, up $1 billion versus the pr

2/11/26 4:10:00 PM ET

Radio And Television Broadcasting And Communications Equipment

Technology

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors Approvals based on Phase 3 KEYNOTE-B96 trial that demonstrated the KEYTRUDA regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared to placebo plus paclitaxel with or without bevacizumab Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or

2/11/26 6:45:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$AKRO
$CNM
$EMN
$FPI
Leadership Updates

Live Leadership Updates

Eastman Schedules Fourth-Quarter and Full-Year 2025 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast, and Release of Additional Information

Eastman Chemical Company (NYSE:EMN): Financial Results Release: Thursday, Jan. 29, 2026 Approximately 4:15 p.m. Eastern Time Via wire distribution and www.eastman.com, News Center and SEC Form 8-K filing. Advance Slides, Webcast and Teleconference: Friday, Jan. 30, 2026 8:00 a.m. Eastern Time Via listen-only live webcast and teleconference. Advance slides and prepared remarks: posted Thursday, Jan. 29, evening at investors.eastman.com Webcast: Eastman Q4 and FY 2025 Webcast to join live webcast Teleconference: Toll-Free dial-in number +1 (833) 470-1428 Passcode: 251637 Teleconference Pre-Registration: To spe

1/12/26 10:00:00 AM ET

Major Chemicals

Industrials

Core & Main Signs Agreement to Acquire Pioneer Supply

Core & Main Inc. (NYSE:CNM), a leader in advancing reliable infrastructure with local service, nationwide, has entered into a definitive agreement to acquire Pioneer Supply, a distributor of water, wastewater and storm drainage products with locations in Moore, Oklahoma, and Weatherford, Texas. "Pioneer Supply represents a wonderful opportunity to expand our presence in Texas and Oklahoma," said Brad Cowles, president of Core & Main. "Their strong reputation for quality and service perfectly complements our mission to deliver exceptional value to our customers. Together, we will be able to expand our reach and create even greater opportunities for growth and success." Established in 196

1/5/26 4:15:00 PM ET

Durable Goods

Consumer Discretionary

Motorola Solutions Appoints Mark Lashier to Board of Directors

Motorola Solutions (NYSE:MSI), a global leader in safety and security technologies, today announced that Mark Lashier has been appointed to its board of directors. Lashier is chairman and chief executive officer at Phillips 66 (NYSE:PSX). A chemical engineer, Lashier has over 30 years of experience in various executive leadership roles within the energy and petrochemical industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118217693/en/Motorola Solutions Appoints Mark Lashier to Board of Directors Credit: Motorola Solutions "I'm pleased to have Mark join our board and welcome a fellow CEO and his experience and insights

11/18/25 4:10:00 PM ET

Radio And Television Broadcasting And Communications Equipment

Technology

Integrated oil Companies

Energy

$AKRO
$CNM
$EMN
$FPI
Financials

Live finance-specific insights

Motorola Solutions Reports Fourth-Quarter and Full-Year Financial Results

Company achieves record full-year revenue, earnings, cash flow and ending backlog Sales of $3.4 billion, up 12% from Q4 in the prior year; up 8% for full year Products and Systems Integration sales grew 11% in Q4; up 5% for full year Software and Services sales grew 15% in Q4; up 13% for full year GAAP Q4 earnings per share (EPS) of $3.86, up 8%; $12.75 for full year, up 38% Non-GAAP Q4 EPS* of $4.59, up 14%; $15.38 for full year, up 11% Generated $1.3 billion of operating cash flow in Q4; $2.8 billion for full year, up 19% Repurchased $490 million of shares and paid $182 million in dividends in Q4 Record ending backlog of $15.7 billion, up $1 billion versus the pr

2/11/26 4:10:00 PM ET

Radio And Television Broadcasting And Communications Equipment

Technology

New Ownership Team Acquires Grizzly Lodge

British Columbia's only full-service backcountry snowmobile lodge enters its next chapter with continuity, experience, and a long-term vision. Accessible only by snow road and helicopter in winter and surrounded by more than 84,500 acres of pristine terrain, Grizzly Lodge has built a global reputation as one of the world's premier backcountry snowmobiling retreats. That legacy will continue under new ownership, the Lodge announced. Business executives and lifelong adventurers Paul Pittman and Palmer Thornton acquired the 12,000-square-foot resort from Adam and Rachel Trainer. Adam will remain actively involved during a transition period. Grizzly Lodge's leadership team of Tom Larivier

2/5/26 7:10:00 AM ET

Real Estate Investment Trusts

Real Estate

REGAL REXNORD REPORTS STRONG FOURTH QUARTER 2025 FINANCIAL RESULTS, INCLUDING ORGANIC GROWTH ACCELERATION AND DATA CENTER ORDERS WORTH ~$735M

MILWAUKEE, Feb. 4, 2026 /PRNewswire/ -- Regal Rexnord Corporation (NYSE:RRX) 4Q Highlights Daily Orders Up 53.8% Versus PY, On Substantial Wins In Data CenterTraction With Data Center E-Pod Solution, Which Embeds Our Proven Switchgear Technology, Winning Orders Worth ~$735 Million. Initial E-Pod Shipments Expected To Start In Early 2027Sales Of $1,523.2 Million, Up 4.3% Versus PY, Up 2.9% On An Organic* BasisGross Margin of 37.5%; Adjusted Gross Margin* Of 37.6%, Up 50 Basis Points Versus PYGAAP Net Income Of $63.8 Million Versus PY Of $42.0 Million, Up $21.8 Million Or 51.9% Versus PYAdjusted EBITDA* Of $328.5 Million Versus PY Of $317.6 Million, Up $10.9 Million Or 3.4% Versus PYDiluted E

2/4/26 4:53:00 PM ET

Metal Fabrications

Consumer Discretionary